Mechanism of Action

SEMA binds to and activates its target incretin receptor, a G-protein-coupled receptor expressed in pancreatic beta cells, the gastrointestinal tract, and specific brain regions including the hypothalamus and hindbrain. Receptor activation initiates cAMP-mediated signaling cascades that potentiate glucose-dependent insulin secretion from pancreatic beta cells.

In the central nervous system, incretin receptor activation in hypothalamic nuclei engages appetite-signaling circuitry, including POMC/CART neuron activation and NPY/AgRP neuron inhibition, as characterized in rodent and cell-based models. Peripheral effects include delayed gastric emptying through vagal afferent signaling and suppression of inappropriate glucagon secretion from pancreatic alpha cells. These descriptions summarize receptor-level pharmacology reported in the literature and are not statements of clinical efficacy or human benefit.

Research Applications

• → The alpha-aminoisobutyric acid substitution at position 8 is studied as a design strategy for resistance to dipeptidyl peptidase-4 cleavage
• → Acylation at Lys26 with a C18 fatty diacid enables reversible, non-covalent albumin binding, extending circulating half-life in published pharmacokinetic models
• → Characterized in receptor-binding studies as a selective agonist at a class B G-protein-coupled receptor with downstream cAMP/PKA signaling
• → Biophysical work has examined the contribution of the fatty-acid linker to peptide self-association and albumin affinity
• → Widely used as an analytical reference standard in LC-MS and HPLC method development for incretin-class peptides

Analytical Validation

SEMA is verified via LC-MS and HPLC analysis. Each lot is tested for identity, purity (≥99% target), and endotoxin levels. Full certificate of analysis is available upon request.